New Alliance Capital logo

New Alliance Capital

Asia, Shanghai, China, Shanghai

Description

New Alliance Capital (NAC) is a private equity fund based in Shanghai, China, established in 2015. The firm positions itself as an investor across various stages, including early, growth, and pre-IPO investments. Its strategic focus lies in identifying high-growth companies that possess strong management teams and disruptive technologies. NAC primarily targets sectors critical to China's economic and technological advancement, specifically healthcare, Technology, Media, and Telecommunications (TMT), and advanced manufacturing, alongside other emerging industries.

The firm's investment philosophy emphasizes long-term partnerships with portfolio companies, aiming to provide not just capital but also strategic guidance to help them scale and achieve market leadership. While their portfolio on platforms like Crunchbase indicates approximately 15 investments to date, their approach suggests a selective process focused on companies poised for significant expansion and eventual public listing or acquisition. This multi-stage investment strategy allows them to support companies from their nascent phases through to maturity.

New Alliance Capital manages a total of $30 million across two distinct funds, with their most recent being New Alliance Capital Fund II. This fund size suggests a disciplined investment approach, likely involving participation in larger syndicated rounds for growth and pre-IPO stages, while potentially leading smaller, earlier-stage rounds. Based on their fund size and investment stages, typical first check sizes for New Alliance Capital are estimated to range from approximately $500,000 for early-stage ventures to around $5,000,000 for more mature growth-stage or pre-IPO opportunities. This range allows them to maintain a diversified portfolio while still making meaningful contributions to their investees.

Investor Profile

New Alliance Capital has backed more than 22 startups, with 6 new investments in the last 12 months alone. The firm has led 2 rounds, about 9% of its total and boasts 8 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Series B, Series D, Series A rounds (top funding stages).
  • Majority of deals are located in China, Israel, United States.
  • Strong thematic focus on Biotechnology, Health Care, Medical.
  • Led 1 rounds in the past year.
  • Typical check size: $500K – $5M.

Stage Focus

  • Series B (27%)
  • Series D (27%)
  • Series A (18%)
  • Series C (9%)
  • Series Unknown (9%)
  • Seed (9%)

Country Focus

  • China (73%)
  • Israel (14%)
  • United States (14%)

Industry Focus

  • Biotechnology
  • Health Care
  • Medical
  • Manufacturing
  • Artificial Intelligence (Ai)
  • Machine Learning
  • Biopharma
  • Software
  • Health Diagnostics
  • Pharmaceutical
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does New Alliance Capital frequently co-invest with?

IDG Capital
Asia, Beijing, China, Beijing
Co-Investments: 2
GO CAPITAL
Europe, Bretagne, France, Rennes
Co-Investments: 2
Aptiv
Europe, Dublin, Ireland, Dublin
Co-Investments: 1
Longliv Ventures
Asia, Tel Aviv, Israel, Herzliya
Co-Investments: 2
OurCrowd
Asia, Yerushalayim, Israel, Jerusalem
Co-Investments: 2
KUNLUN
Asia, Beijing, China, Beijing
Co-Investments: 2
Huajin Capital
Asia, Guangdong, China, Zhuhai
Co-Investments: 2
HongShan
Asia, Beijing, China, Beijing
Co-Investments: 3
Qiming Venture Partners
Asia, Shanghai, China, Shanghai
Co-Investments: 2
Haitong Capital
Europe, Lisboa, Portugal, Lisbon
Co-Investments: 2

Which angels does New Alliance Capital often collaborate with?

Shared Deals: 1
Shared Deals: 1

What are some of recent deals done by New Alliance Capital?

Leju Robotics

Shenzhen, Guangdong, China

Leju Robotics focuses on researching and developing, marketing, and manufacturing of robot.

Consumer ElectronicsMachinery ManufacturingManufacturingRobotics
Series UnknownJun 10, 2025
Core Medical Technology

Shenzhen, Guangdong, China

Core Medical Technology develops ventricular assist devices and equipment.

ManufacturingMedicalMedical Device
Series DApr 24, 2025
Amount Raised: $100,000,000
Pu Enjing

Shanghai, Shanghai, China

Pu Enjing engaged in the independent research and development of high-end polymer materials.

ChemicalIndustrialMarket Research
Series BJan 22, 2025
Huali Juneng

Wuxi Shi, Jiangsu, China

Huali Juneng is a pressure vessel and related equipment producer company.

Manufacturing
SeedNov 18, 2024
Amount Raised: $110,552,208
Positive Sequence Biology

Shanghai, Shanghai, China

Positive Sequence Biology is a biotech company with new gene system-based editing, focused on biotech innovation & breakthrough therapies.

BiopharmaBiotechnologyGenetics
Series AAug 8, 2024
Amount Raised: $13,938,059
Stepin

Guangzhou, Guangdong, China

Stepin is a cross-border jewelry brand that specializes in AI jewelry cross-border e-commerce.

E-CommerceRetail
SeedAug 5, 2024
Amount Raised: $1,404,258
Arnatar Therapeutics

San Diego, California, United States

Arnatar Therapeutics is a biopharmaceutical company that specializes in the development of novel nucleic acid medications.

BiopharmaMedical
Series AApr 8, 2024
Amount Raised: $50,000,000
Guanan Information

Jiading, Shanghai, China

Guanan Information specializes in serving the information security market by offering the service of big data & information security.

Big DataCloud SecurityCyber SecurityInformation TechnologyNetwork Security
Series UnknownFeb 3, 2023
Amount Raised: $44,279,789
Kactus Biosystems

Shanghai, Shanghai, China

Kactus Biosystems is a biotechnology company that designs and manufactures high-quality and bioactive recombinant proteins.

BiotechnologyHealth Care
Series BOct 19, 2022
Amount Raised: $26,283,754
Harvest Integrated Research Organization

Excelsior, Minnesota, United States

Harvest Integrated Research Organization (HiRO) is a globally oriented, innovative clinical research organization (CRO).

BiopharmaBiotechnologyClinical TrialsMedicalPharmaceutical
Series AMar 18, 2022
Amount Raised: $1,572,030